Illumina, Emedgene Launch AI-Based Rare Disease Interpretation Partnership
Illumina has launched a nonexclusive partnership with Emedgene, an artificial intelligence-based precision medicine company, to integrate automated interpretation of rare genetic disease data into Illumina’s TruSight™ Software Suite.
Through the collaboration, whose value has not been disclosed, TruSight will include Emedgene’s clinical rare disease application, one of a portfolio of artificial intelligence (AI)-powered applications for high-throughput genomic interpretation across clinical and research use cases.
Illumina and Emedgene reason that through AI-enhanced interrogation of medical literature and phenotypes associated with rare disease, researchers will be better able to make new and unexpected discoveries based on rare disease data.